IVERIC bio has been granted a patent for novel carbocyclic prolinamide derivatives effective in preventing and treating age-related macular degeneration and related eye diseases. The compounds are HTRA1 inhibitors, offering potential therapeutic benefits for various conditions. GlobalData’s report on IVERIC bio gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on IVERIC bio, Peptide pharmacophores was a key innovation area identified from patents. IVERIC bio's grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent (Publication Number: US11866422B2) discloses a compound of Formula I as claimed in the patent. The compound described in the patent is likely a specific chemical structure that has been identified and patented for a particular use or application. The formula provided in the claim serves as a unique identifier for the compound, allowing researchers and professionals in the field to easily reference and understand the chemical composition being protected by the patent.
The compound of Formula I mentioned in the patent is likely the subject of extensive research and development, indicating its potential significance in various industries such as pharmaceuticals, materials science, or agriculture. The specific details of the compound, including its structure and properties, are likely crucial for understanding its potential applications and benefits. This patent protection ensures that the inventors or assignees have exclusive rights to the compound, allowing them to commercialize it and potentially bring new products or technologies to the market based on the unique properties of the compound.
To know more about GlobalData’s detailed insights on IVERIC bio, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
